SHAANXI MEIBANG PHARMACEUTICAL GROUP CO., LTD. Financials Shaanxi Meibang Pharmaceutical Group Co., Ltd.
Equities
605033
CNE100005071
Agricultural Chemicals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.76 CNY | -3.13% |
|
+0.86% | -34.48% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 3,611 | 2,359 | 2,427 |
| Enterprise Value (EV) 1 | 3,236 | 1,961 | 1,946 |
| P/E ratio | 23.4 x | 16 x | 41.7 x |
| Yield | 0.71% | 1.29% | 0.84% |
| Capitalization / Revenue | 4.29 x | 2.6 x | 3.47 x |
| EV / Revenue | 3.84 x | 2.16 x | 2.78 x |
| EV / EBITDA | 23.9 x | 13 x | 31.1 x |
| EV / FCF | -10.7 x | -39.5 x | 14.7 x |
| FCF Yield | -9.38% | -2.53% | 6.82% |
| Price to Book | 3.73 x | 2.17 x | 2.18 x |
| Nbr of stocks (in thousands) | 135,200 | 137,793 | 135,200 |
| Reference price 2 | 26.71 | 17.12 | 17.95 |
| Announcement Date | 19/04/22 | 19/04/23 | 25/04/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 438.6 | 515.7 | 568.5 | 842.5 | 906 | 699 |
| EBITDA 1 | 79.74 | 97.79 | 95.48 | 135.5 | 150.7 | 62.51 |
| EBIT 1 | 71.61 | 87.65 | 85.01 | 123.1 | 135.2 | 42.9 |
| Operating Margin | 16.33% | 17% | 14.95% | 14.61% | 14.93% | 6.14% |
| Earnings before Tax (EBT) 1 | 67.42 | 85.5 | 89.39 | 138.8 | 152.4 | 62.41 |
| Net income 1 | 59.33 | 76.26 | 78.73 | 125.7 | 145.1 | 57.56 |
| Net margin | 13.53% | 14.79% | 13.85% | 14.93% | 16.01% | 8.23% |
| EPS 2 | 0.6000 | 0.7500 | 0.7800 | 1.140 | 1.070 | 0.4300 |
| Free Cash Flow 1 | -72.91 | 68.42 | -13.39 | -303.5 | -49.7 | 132.8 |
| FCF margin | -16.63% | 13.27% | -2.36% | -36.02% | -5.49% | 18.99% |
| FCF Conversion (EBITDA) | - | 69.96% | - | - | - | 212.4% |
| FCF Conversion (Net income) | - | 89.72% | - | - | - | 230.68% |
| Dividend per Share | - | - | - | 0.1900 | 0.2200 | 0.1500 |
| Announcement Date | 20/11/20 | 20/11/20 | 26/04/21 | 19/04/22 | 19/04/23 | 25/04/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 68.7 | 182 | 199 | 375 | 398 | 481 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -72.9 | 68.4 | -13.4 | -303 | -49.7 | 133 |
| ROE (net income / shareholders' equity) | 26% | 23.6% | 19.2% | 17.8% | 14.1% | 5.23% |
| ROA (Net income/ Total Assets) | 8.17% | 8.75% | 7.32% | 6.84% | 5.59% | 1.65% |
| Assets 1 | 726.1 | 871.3 | 1,076 | 1,839 | 2,595 | 3,491 |
| Book Value Per Share 2 | 2.790 | 3.660 | 4.430 | 7.150 | 7.880 | 8.240 |
| Cash Flow per Share 2 | 0.7100 | 2.050 | 1.970 | 1.880 | 2.310 | 3.560 |
| Capex 1 | 34.9 | 33.8 | 61.7 | 107 | 109 | 204 |
| Capex / Sales | 7.95% | 6.55% | 10.85% | 12.64% | 12.06% | 29.14% |
| Announcement Date | 20/11/20 | 20/11/20 | 26/04/21 | 19/04/22 | 19/04/23 | 25/04/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -34.48% | 219M | |
| -12.52% | 3.1B | |
| -45.71% | 1.46B | |
| -15.35% | 1.44B | |
| -21.79% | 1.42B | |
| -35.59% | 1.38B | |
| -13.03% | 1.19B | |
| -13.92% | 978M | |
| +59.89% | 938M | |
| -35.17% | 856M |
- Stock Market
- Equities
- 605033 Stock
- Financials Shaanxi Meibang Pharmaceutical Group Co., Ltd.
